Efficient Synthesis of α- and β-2′-Deoxy-heteroaryl-C-nucleosides

Marie Spadafora; Alain Burger; Rachid Benhida

doi:10.1055/s-2008-1072589

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synlett 2008(8): 1225-1229
DOI: 10.1055/s-2008-1072589

LETTER

Efficient Synthesis of α- and β-2′-Deoxy-heteroaryl-C-nucleosides

Marie Spadafora, Alain Burger*, Rachid Benhida*
Laboratoire de Chimie des Molécules Bioactives et des Arômes, UMR 6001 CNRS, Institut de Chimie de Nice, Université de Nice-Sophia Antipolis, 28 Avenue de Valrose, 06108 Nice Cedex 2, France
Fax: +33(4)92076151; e-Mail: benhida@unice.fr;

Further Information

Publication History

Received 22 January 2008
Publication Date:
16 April 2008 (online)

Abstract
Full Text
References

Permissions and Reprints All articles of this category

Abstract

A short and efficient method for the synthesis of a series of 2′-deoxy-heteroaryl-C-nucleosides has been developed by the application of aryl-aldol condensation followed by p-toluenesulfonic acid (PTSA)-mediated isopropylidene cleavage and subsequent cycloetherification.

Key words

C-nucleosides - aryl-aldol condensation - cycloetherification

References and Notes

For recent reviews on the chemistry of C-glycoside analogues, see:
1a Wu Q. Simons C. Synthesis 2004, 1533

Crossref PubMed Google Scholar
1b Bililign T. Griffith BR. Thorson JS. Nat. Prod. Rep. 2005, 22: 742

Crossref PubMed Google Scholar
1c Lee DYW. He MS. Curr. Top. Med. Chem. 2005, 5: 1333

Crossref PubMed Google Scholar
For a brief overview of the biological and clinical impact of tiazofurin, see:
2a For pyrazofurin and formycin, see: Grifantini M. Curr. Opin. Investig. Drugs 2000, 1: 257

Crossref Google Scholar
2b Shaban MAE. Nasr AZ. In Advances in Heterocyclic Chemistry Vol. 68: Katritzky AR. Academic Press; San Diego: 1997. p.259

Crossref Google Scholar
2c For showdomycin, see: Shaban MAE. Nasr AZ. In Advances in Heterocyclic Chemistry Vol. 70: Katritzky AR. Academic Press; San Diego: 1998. p.230

Crossref Google Scholar
2d Nishimura H. Mayama M. Komatsu Y. Kato H. Shimsoka N. Tanaka Y. J. Antibiot., Ser. A 1964, 17: 148

Crossref Google Scholar
2e Rabinovitz M. Uehara Y. Vistica DT. Science 1979, 206: 1085

Crossref Google Scholar
2f Barett AGM. Broughton HB. J. Org. Chem. 1986, 51: 495

Crossref Google Scholar
3a Adamo MFA. Adlington RM. Baldwin JE. Day AL. Tetrahedron 2004, 60: 841

Crossref Google Scholar
3b Hashmi IA. Ali FI. Feist H. Michalik M. Reinke H. Peseke K. Synthesis 2007, 2819

Crossref Google Scholar
3c Oda H. Hanami T. Iwashita T. Kojima M. Itoh M. Hayashizaki Y. Tetrahedron 2007, 63: 11021

Crossref Google Scholar
3d Hainke S. Singh I. Hemmings J. Seitz O. J. Org. Chem. 2007, 72: 8811

Crossref Google Scholar
4a Kool ET. Acc. Chem. Res. 2002, 35: 936

Crossref Google Scholar
4b Sismour AM. Benner SA. Nucleic Acids Res. 2005, 33: 5640

Crossref Google Scholar
4c Leconte AM. Matsuda S. Hwang GT. Romesberg FE. Angew. Chem. Int. Ed. 2006, 45: 4326

Crossref Google Scholar
See, for example:
5a Tanaka K. Shinoya M. J. Org. Chem. 1999, 64: 5002

Crossref Google Scholar
5b Seela F. Debelak H. J. Org. Chem. 2001, 66: 3303

Crossref Google Scholar
See, for example:
6a Chen D.-W. Beuscher AE. Stevens RC. Wirsching P. Lerner RA. Janada KD. J. Org. Chem. 2001, 66: 1725

Crossref PubMed Google Scholar
6b Griesang N. Richert C. Tetrahedron Lett. 2002, 43: 8755

Crossref PubMed Google Scholar
6c Aketani S. Tanaka K. Yamamoto K. Ishihama A. Cao H. Tengeiji A. Hiraoka S. Shiro M. Shionoya M. J. Med. Chem. 2002, 45: 5594

Crossref PubMed Google Scholar
7a For the synthesis of aryl C-glycosides via the Heck reaction, see: Wellington KW. Benner SA. Nucleosides, Nucleotides Nucleic Acids 2005, 1309 ; (review)

Crossref Google Scholar
7b Oda H. Hanami T. Iwashita T. Kojima M. Itoh M. Hayashizaki Y. Tetrahedron 2007, 63: 12747

Crossref Google Scholar
8a Guianvarc’h D. Benhida R. Fourrey J.-L. Maurisse R. Sun J.-S. Chem. Commun. 2001, 1814

Crossref Google Scholar
8b Guianvarc’h D. Fourrey J.-L. Sun J.-S. Maurisse R. Benhida R. Bioorg. Med. Chem. 2003, 11: 2751

Crossref Google Scholar
8c Guianvarc’h D. Fourrey J.-L. Tran Huu Dau M.-E. Guérineau V. Benhida R. J. Org. Chem. 2002, 67: 3724

Crossref Google Scholar
8d Guianvarc’h D. Fourrey J.-L. Maurisse R. Sun J.-S. Benhida R. Org. Lett. 2002, 4: 4209

Crossref Google Scholar
9 Ratiometric fluorescent probes will be used (unpublished results). For classical fluorescent nucleosides, see: Wilson JN. Kool ET. Org. Biomol. Chem. 2006, 4: 4265

Crossref Google Scholar
10a Joos PE. Esmans EL. Domise RA. De Bruyn A. Balzarini JM. De Clercq ED. Helv. Chim. Acta 1992, 75: 613

Google Scholar
10b
Aldehyde 1 was obatined from 2′-deoxyribose in four steps and 62% overall yield.
13 Jiang YL. Stivers JT. Tetrahedron Lett. 2003, 44: 4051

Crossref Google Scholar

11

Typical Procedure To a solution of benzofuran (2 mmol) in anhyd THF (6 mL) was added dropwise n-BuLi (1.6 M in hexane, 2 mmol) at 0 °C. The mixture was stirred for 30 min and aldehyde 1 (412 mg, 1 equiv) in anhyd THF (2 mL) was slowly added. The reaction was stirred during 90 min and warmed slowly to r.t., then quenched with a cold solution of NH₄Cl and extracted with CH₂Cl₂ (3 × 40 mL). The combined organic layers were dried (MgSO₄) and evaporated under reduced pressure to give a crude oil. Silica gel column chroma-tography purification using gradient elution [cyclohexane (100%) to EtOAc-cyclohexane (8:92)] afforded (S)-2a and (R)-2a as yellow oils (440 mg, 83%, R/S = 35:65).
Compound (S)-2a: TLC (cyclohexane-EtOAc, 7:3). R _f = 0.49. ¹H NMR (200 MHz, CDCl₃): δ = 0.95 (s, 9 H, t-Bu), 1.28 (s, 3 H, CH₃), 1.37 (s, 3 H, CH₃), 2.06-2.27 (m, 1 H, H-2′), 2.37-2.47 (m, 1 H, H-2′), 3.72 (d, 2 H, J = 6.3 Hz, 2 × H-5′), 4.30 (q, 1 H, J = 6.2 Hz, H-4′), 4.42-4.52 (m, 1 H, H-3′), 5.12 (dd, 1 H, J = 3.8, 8.7 Hz, H-1′), 6.67 (s, 1 H, H-furan), 7.26 (m, 2 H, 2 × H-Ar), 7.36 (m, 7 H, 6 × H-Ph and 1 × H-Ar), 7.55 (m, 1 H, H-Ar), 7.64 (m, 4 H, 4 × H-Ph) ppm. ¹³C NMR (50 MHz, CDCl₃): δ = 19.10 (Me₃ C), 25.44 (Me ₂C), 26.75 (Me ₃C), 27.91 (Me ₂C), 35.36 (C-2′), 62.19 (C-5′), 68.14 (C-1′), 76.85 (C-3′), 77.51 (C-4′), 102.49 (C-3), 108.78 (Me₂ C), 111.15 (C-7), 120.96 (C-4), 122.63 (C-5), 123.92 (C-6), 127.70 (C-Ph), 127.72 (C-Ar), 129.77, 132.90, and 135.51 (C-Ph), 154.75 (C-Ar), 158.64 (C-2) ppm. MS (ESI⁺): m/z = 568.5 [MK⁺], 552.6 [MNa⁺].
Compound (R)-2a: TLC (cyclohexane-EtOAc, 7:3). R _f = 0.40. ¹H NMR (200 MHz, CDCl₃): δ = 1.00 (s, 9 H, t-Bu), 1.26 (s, 3 H, CH₃), 1.38 (s, 3 H, CH₃), 2.22-2.45 (m, 2 H, 2 × H-2′), 3.69-3.74 (m, 2 H, 2 × H-5′), 4.20-4.29 (m, 1 H, H-4′), 4.42-4.52 (m, 1 H, H-3′), 5.08-5.16 (m, 1 H, H-1′), 6.65 (s, 1 H, H-furan), 7.26 (m, 2 H, 2 × H-Ar), 7.36 (m, 7 H, 6 × H-Ph and 1 × H-Ar), 7.55 (m, 1 H, H-Ar), 7.64 (m, 4 H, 4 × H-Ph) ppm. ¹³C NMR (50 MHz, CDCl₃): δ = 19.19 (Me₃ C), 25.54 (Me ₂C), 26.86 (Me ₃C), 28.08 (Me ₂C), 34.12 (C-2′), 62.36 (C-5′), 66.52 (C-1′), 74.52 (C-3′), 77.48 (C-4′), 102.69 (C-3), 108.35 (Me₂ C), 111.21 (C-7), 120.99 (C-4), 122.75 (C-5), 123.97 (C-6), 127.79 (C-Ph), 128.30 (C-Ar), 129.87, 133.04, and 135.62 (C-Ph), 154.90 (C-Ar), 159.56 (C-2) ppm. MS (ESI⁺): m/z = 552.6 [MNa⁺], 450.7.

12

All products gave satisfactory spectral data. Data for selected products are given here.
Compound (R,S)-2b: TLC (cyclohexane-EtOAc, 7:3): R _f = 0.70-0.75. ¹H NMR (200 MHz, CDCl₃): δ = 1.04 (s, 9 H, t-Bu), 1.34 (s, 3 H, CH₃), 1.41 (s, 3 H, CH₃), 1.50-2.2 (m, 2 H, H-2′), 3.68-3.71 (m, 2 H, 2 × H-5′), 4.21-4.42 (m, 2 H, H-4′, H-3′), 4.88-4.95 (m, 1 H, H-1′), 6.25-6.26 (m, 2 H, 2 × H-Ar), 7.38-7.41 (m, 7 H, 6 × H-Ph, 1 × H-Ar), 7.62-7.66 (m, 4 H, 4 × H-Ph) ppm. ¹³C NMR (50 MHz, CDCl₃): δ = 19.29 (Me₃ C), 25.66 (Me ₂C), 26.93 (Me ₃C), 28.14 (Me ₂C), 35.40 (C-2′), 62.43 (C-5′), 67.64-65.66 (C-1′), 76.54-74.36 (C-3′), 77.18 (C-4′), 106.01-108.69 (C-Ar), 108.83 (Me₂ C), 110.26-111.95 (C-Ar), 127.91, 129.96, 133.17, 135.70, 142.03 (C-Ph and C-Ar) ppm. MS (ESI⁺):
m/z = 503.2 [MNa⁺].
Compound (R,S)-2e: TLC (cyclohexane-EtOAc, 7:3). R _f = 0.50-0.53. ¹H NMR (200 MHz, CDCl₃): δ = 0.96 (s, 9 H, t-Bu), 1.27 (s, 3 H, CH₃), 1.31 (s, 3 H, CH₃), 1.50-2.11 (m, 2 H, H-2′), 3.59-3.65 (m, 2 H, 2 × H-5′), 4.12-4.22 (m, 1 H, H-4′), 4.30-4.37 (m, 1 H, H-3′), 5.00-5.10 (m, 0.4 H, H-1′), 5.11-5.20 (m, 0.6 H, H-1′), 6.80-6.89 (m, 2 H, 2 × H-Ar), 7.20-7.26 (m, 1 H, H-Ar), 7.30-7.40 (m, 6 H, 6 × H-Ph), 7.52-7.58 (m, 4 H, 4 × H-Ph) ppm. ¹³C NMR (50 MHz, CDCl₃): δ = 19.29 (Me₃ C), 25.63 (Me ₂C), 26.98 (Me ₃C), 28.17 (Me ₂C), 37.91 (C-2′), 62.54 (C-5′), 68.01 (C-1′), 77.37 (C-3′), 77.62 (C-4′), 108.42 (Me₂ C), 123.27, 124.43, 126.85, 127.88, 129.96, 133.10, 135.69, 149.07 (C-Ph and C-Ar) ppm. MS (ESI⁺): m/z = 534.6 [MK⁺], 518.7 [MNa⁺], 497.6 [MH⁺].

14

General Procedure
To a solution of 2a (R or S, 1 mmol) in toluene (25 mL) was added PTSA (0.2 mmol, 0.2 equiv). The mixture was stirred at 50 °C for 4 h then quenched with a sat. soln of NaHCO₃ and extracted with CH₂Cl₂ (3 × 30 mL). The combined organic layers were dried over MgSO₄ and evaporated under reduced pressure to give a crude oil. Silica gel column chromatography purification using gradient elution [cyclohexane (100%) to EtOAc-cyclohexane (20:80)] afforded 3a as a yellow oil.
Compound α-3a: TLC (cyclohexane-EtOAc, 7:3). R _f = 0.43. ¹H NMR (200 MHz, CDCl₃): δ = 1.08 (s, 9 H, t-Bu), 2.27-2.39 (m, 1 H, H-2′), 2.66-2.80 (m, 1 H, H-2′), 3.69-3.88 (m, 2 H, 2 × H-5′), 4.16-4.20 (m, 1 H, H-4′), 4.52-4.59 (m, 1 H, H-3′), 5.24-5.31 (dd, 1 H, J = 8.0, 5.3 Hz, H-1′), 6.69 (s, 1 H, H-furan), 7.39-7.66 (m, 10 H, 6 × H-Ph and 4 × H-Ar), 7.67-7.71 (m, 4 H, 4 × H-Ph) ppm. ¹³C NMR (50 MHz, CDCl₃): δ = 19.40 (Me₃ C), 27.05 (Me ₃C), 39.40 (C-2′), 64.98 (C-5′), 74.04 and 74.78 (C3′, C-1′), 86.53 (C-4′), 103.95, 111.48, 121.31, 123.03, 124.54, 127.97, 129.99, 135.75, 156.72 (C-Ph and C-Ar) ppm. MS (ESI⁺): m/z = 510.8 [MK⁺], 495.1 [MNa⁺].
Compound β-3a: TLC (cyclohexane-EtOAc, 7:3): R _f = 0.26. ¹H NMR (200 MHz, CDCl₃): δ = 1.07 (s, 9 H, t-Bu), 2.20-2.42 (m, 1 H, H-2′), 2.47-2.56 (m, 1 H, H-2′), 3.68-4.01 (m, 2 H, 2 × H-5′), 4.02-4.07 (m, 1 H, H-4′), 4.62-4.67 (m, 1 H, H-3′), 5.30 (dd, 1 H, J = 9.3, 6.2 Hz, H-1′), 6.63 (s, 1 H, H-furan), 7.31-7.60 (m, 10 H, 6 × H-Ph and 4 × H-Ar), 7.62-7.79 (m, 4 H, 4 × H-Ph) ppm. ¹³C NMR (50 MHz, CDCl₃): δ = 19.40 (Me₃ C), 27.05 (Me ₃C), 39.56 (C-2′), 64.77 (C-5′), 73.82 (C-1′), 74.40 (C-3′), 87.22 (C-4′), 104.08, 111.43, 121.16, 122.81, 124.34, 127.90, 129.96, 135.74, 156.72 (C-Ph and C-Ar) ppm. MS (ESI⁺):
m/z = 510.8 [MK⁺], 495.1 [MNa⁺].

15

Compound α-4a: TLC (CH₂Cl₂-MeOH, 98:2). R _f = 0.3. ¹H NMR (500 MHz, CDCl₃): δ = 2.33-2.37 (m, 1 H, H-2′), 2.61-2.64 (m, 1 H, H-2′), 3.73-3.76 (m, 2 H, 2 × H-5′), 4.01-4.04 (q, 1 H, J = 4.7 Hz, H-4′), 4.43-4.45 (q, 1 H, J = 5.7 Hz, H-3′), 5.21 (t, 1 H, J = 6.9 Hz, H-1′), 6.67 (s, 1 H, H-furan), 7.16-7.20 (t, 1 H, J = 7.2 Hz, H-Ar), 7.22-7.25 (m, 1 H, H-Ar), 7.42 (d, 1 H, J = 8.2 Hz, H-Ar), 7.50 (d, 1 H, J = 7.6 Hz, H-Ar) ppm. ¹³C NMR (CDCl₃, 125 MHz): δ = 39.23 (C-2′), 58.74 (C-5′), 62.74 (C-3′), 73.23 (C-1′), 85.69 (C-4′), 103.95 (C-3), 111.35 (C-7), 121.85 (C-4), 122.87 (C-5), 124. (C-6), 128.15 (C-Ar), 154.75 (C-Ar), 157.30 (C-2) ppm. MS (ESI⁺): m/z = 256.7 [MNa⁺], 241.9 [MLi⁺], 214.7 [M⁺ - H₂O].
Compound β-4a: TLC (CH₂Cl₂-MeOH, 98:2). R _f = 0.28. ¹H NMR (500 MHz, CDCl₃): δ = 2.17-2.30 (m, 1 H, H-2′), 2.45-2.51 (m, 1 H, H-2′), 3.75 (d, 2 H, J = 4.4 Hz, 2 × H-5′), 4.05 (m, 1 H, H-4′), 4.56 (m, 1 H, H-3′), 5.30 (dd, 1 H, J = 6.6, 8.8 Hz, H-1′), 6.67 (s, 1 H, H-furan), 7.18-7.21 (m, 1 H, H-Ar), 7.22-7.25 (m, 1 H, H-Ar), 7.45 (d, 1 H, J = 8.3 Hz, H-Ar), 7.52 (d, 1 H, J = 7.8 Hz, H-Ar) ppm. ¹³C NMR (125 MHz, CDCl₃): δ = 39.91 (C-2′), 58.82 (C-5′), 63.54 (C-3′), 73.78 (C-1′), 87.73 (C-4′), 104.23 (C-3), 111.45 (C-7), 121.12 (C-4), 122.89 (C-5), 124.46 (C-6), 128.15 (C-Ar), 155.18 (C-Ar), 156.81 (C-2) ppm. MS (ESI⁺): m/z = 256.7 [MNa⁺], 241.9 [MLi⁺], 214.7 [M⁺ - H₂O].